$13.53
2.81% yesterday
Nasdaq, Aug 12, 10:16 pm CET
ISIN
US86150R1077
Symbol
STOK

Stoke Therapeutics Inc Stock price

$13.53
+1.47 12.19% 1M
+3.27 31.87% 6M
+2.50 22.67% YTD
-0.92 6.33% 1Y
-8.07 37.36% 3Y
-14.93 52.46% 5Y
-4.47 24.83% 10Y
-4.47 24.83% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.37 2.81%
ISIN
US86150R1077
Symbol
STOK
Industry

Key metrics

Basic
Market capitalization
$718.5m
Enterprise Value
$361.2m
Net debt
positive
Cash
$357.3m
Shares outstanding
54.6m
Valuation (TTM | estimate)
P/E
15.7 | 215.0
P/S
3.8 | 3.9
EV/Sales
1.9 | 1.9
EV/FCF
5.2
P/B
2.1
Financial Health
Equity Ratio
84.3%
Return on Equity
-38.9%
ROCE
10.6%
ROIC
137.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$190.9m | $186.1m
EBITDA
$40.3m | $-932.8k
EBIT
$38.2m | $-20.7m
Net Income
$50.3m | $3.3m
Free Cash Flow
$69.2m
Growth (TTM | estimate)
Revenue
2,332.0% | 409.1%
EBITDA
134.8% | 99.1%
EBIT
132.3% | 79.6%
Net Income
146.3% | 103.8%
Free Cash Flow
180.7%
Margin (TTM | estimate)
Gross
-
EBITDA
21.1% | -0.5%
EBIT
20.0%
Net
26.3% | 1.8%
Free Cash Flow
36.3%
More
EPS
$0.8
FCF per Share
$1.3
Short interest
25.5%
Employees
128
Rev per Employee
$290.0k
Show more

Is Stoke Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Stoke Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Stoke Therapeutics Inc forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Stoke Therapeutics Inc forecast:

Buy
88%
Hold
12%

Financial data from Stoke Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
191 191
2,332% 2,332%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 53 53
29% 29%
28%
- Research and Development Expense 99 99
17% 17%
52%
40 40
135% 135%
21%
- Depreciation and Amortization 2.09 2.09
14% 14%
1%
EBIT (Operating Income) EBIT 38 38
132% 132%
20%
Net Profit 50 50
146% 146%
26%

In millions USD.

Don't miss a Thing! We will send you all news about Stoke Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Stoke Therapeutics Inc Stock News

Neutral
Business Wire
about 5 hours ago
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the ...
Neutral
Business Wire
one day ago
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Zorevun...
Neutral
Business Wire
6 days ago
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host...
More Stoke Therapeutics Inc News

Company Profile

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues, including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Head office United States
CEO Ian Smith
Employees 128
Founded 2014
Website www.stoketherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today